GlassScriptPhysician profile
Georgy Cherkassky
NPI 1760827778
$1,609.38
in general payments reported to CMS, 2019-2025
27 companies · $25.61 in 2025
The $25.61 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $303 · 2021: $26.39 · 2025: $25.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $334.62 | 2019-2020 | |
| Biogen, INC. | $214.81 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $130.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $114.87 | 2019 | |
| Abbott Laboratories | $103.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.21 | 2020-2021 | |
| Amgen INC. | $74.80 | 2019-2020 | |
| Kyowa Kirin, INC. | $57.39 | 2019-2020 | |
| Genzyme Corporation | $52.52 | 2019-2020 | |
| Allergan, INC. | $45.49 | 2019-2020 | |
| Acorda Therapeutics, INC | $40.02 | 2019 | |
| Strongbridge US INC. | $40.01 | 2019-2020 | |
| Lilly USA, LLC | $36.39 | 2019 | |
| Ucb, INC. | $29.38 | 2019 | |
| Avanir Pharmaceuticals, INC. | $29.12 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $27.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.61 | 2019-2020 | |
| Merz North America, INC. | $25.98 | 2019 | |
| Boston Scientific Corporation | $25.61 | 2025 | Wallflex Biliary Transhepatic |
| Genentech USA, INC. | $23.89 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.95 | 2020 | |
| Upsher-Smith Laboratories LLC | $14.86 | 2020 | |
| Tanabe Pharma America, INC. | $14.05 | 2019 | |
| Akcea Therapeutics, INC. | $14.01 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.78 | 2020 | |
| Endo Pharmaceuticals INC. | $12.77 | 2020 | |
| Pfizer INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgy Cherkassky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.